Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIDIT-II: PegIFN-alfa2a +/- Tenofovir for Chronic Delta Hepatitis
NCT00932971Phase 2Completed
- Start
- Jun 2009
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in hepatitis D (HDV) comparing PegIFN + Tenofovir with PegIFN + Placebo (2 arms). Primary endpoint: Negativation of HDV-RNA at the end of therapy at 96 weeks. Started Jun 2009; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT00932971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932971.